Nektar Therapeutics is making Phase III preparations for rezpegaldesleukin, also known as rezpeg, after the potential pipeline-in-a-product hit its main goal in a mid-stage trial for patients with atopic dermatitis.
Key Takeaways
- Rapid onset of EASI reduction and magnitude of itch improvement show the potential differentiation of this regulatory T-cell mechanism as a first- and best-in-class immune modulator, Nektar claims.
Shares in the US biotech rocketed 156% to close at $24.25 on 24 June on the back of positive results...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?